San Francisco, CA-based venture capital firm Pivotal bioVenture Partners closed its first fund, at over $300m.
Funded by Hong Kong based Nan Fung Group, Pivotal bioVenture Partners Fund I aims to invest in early stage biotechnology companies.
Led by Dr. Tracy Saxton, PhD, MBA and Mr. Vincent Cheung, Pivotal has an investment strategy centered on identifying companies developing differentiated science from discovery to early clinical development with the potential to deliver transformative therapies.
Prior to co-founding Pivotal, Dr. Saxton was an investor with the Roche Venture Fund and SV Life Sciences Advisers where she focused on biopharmaceutical investments. She is joined by Dr. Karoly Nikolich, PhD, who serves as an advisor and Venture Partner bringing 25 years of senior executive experience.
PIVOTAL BIOVENTURE PARTNERS
English EON: Enhanced Online News
Media and Investors:
Pivotal bioVenture Partners
Tracy Saxton, 415-697-1002
Julie Normart, 415-946-1087
Log InSign Up
More from Business Wire